RE:RE:RE:RE:RE:RE:RE:First Patient Dosed in Phase 1 Trial of TH1902 I suppose you could say the stock is now subject to higher risk newsflow (pass/no pass), which it is. We've spent the last year risk-assessing it so I think we have a better understanding, but as many hear always say, the human body is a tricky scientific subject.
I'll have to go back and look at the clinicaltrials site, but I guess they need to get another 8-9 people in the dose escalation part and then fully get them through the treatment cycle before they'll have any data to share.
qwerty22 wrote: Let's see if the pattern holds. Thtx put's out sciencey stuff and the vol and SP goes crazy. Thtx puts out important milestone info and the market gives a collective shrug.